3,152,456 Shares in Septerna, Inc. (NASDAQ:SEPN) Bought by Trv Gp Vi LLC

TRV GP VI LLC bought a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,152,456 shares of the company's stock, valued at approximately $72,191,000. Septerna accounts for 61.7% of TRV GP VI LLC's portfolio, making the stock its biggest holding. TRV GP VI LLC owned 7.10% of Septerna as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SEPN. Vanguard Group Inc. bought a new stake in Septerna in the fourth quarter valued at $22,557,000. Geode Capital Management LLC bought a new stake in shares of Septerna during the fourth quarter valued at approximately $8,717,000. Charles Schwab Investment Management Inc. purchased a new stake in Septerna in the fourth quarter worth $3,197,000. Bank of New York Mellon Corp bought a new position in Septerna in the fourth quarter worth $872,000. Finally, JPMorgan Chase & Co. purchased a new position in Septerna during the fourth quarter valued at $871,000.

Insider Buying and Selling at Septerna

In other news, CFO Gil M. Labrucherie acquired 10,500 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was bought at an average price of $5.51 per share, with a total value of $57,855.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,500 shares of the company's stock, valued at approximately $57,855. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $6.35 per share, with a total value of $47,567.85. Following the transaction, the director now owns 24,911 shares of the company's stock, valued at $158,184.85. The trade was a 43.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 74,346 shares of company stock worth $439,670.

Wall Street Analyst Weigh In

SEPN has been the topic of a number of recent research reports. Wells Fargo & Company reduced their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, March 28th. Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Stock Performance

NASDAQ:SEPN traded down $0.04 on Friday, reaching $6.43. 104,053 shares of the stock traded hands, compared to its average volume of 428,045. The stock's fifty day moving average is $5.96. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. On average, equities research analysts predict that Septerna, Inc. will post -7.11 EPS for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.